[文献资料]参 考 文 献

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:a randomised controlled trial.And trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer（BCIRG 007 study）：two highly ......